We recently published a list of 10 Stocks Investors Dumped Fast. In this article, we are going to take a look at where ...

Michele Johnson, partner with Latham & Watkins, is among the recipients of the The Recorder's 2025 Women Leaders in Tech Law, ...

We recently published a list of Was Jim Cramer Right About These 11 Stocks? In this article, we are going to take a look at where Sarepta Therapeutics Inc. (NASDAQ:SRPT) stands against other stocks ...

The findings support the clinical benefits of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) ...

The Platform Technology Designation, which predates the current FDA leadership, is designed to streamline the drug ...

Sarepta Therapeutics Inc.’s stock tumbled 23% on Tuesday after the biotech said a patient who used its gene therapy Elevidys for the rare disease Duchenne muscular dystrophy has died of acute ...

The company is one of the first to receive a “platform technology designation,” which could speed the review of certain gene ...

Sarepta Therapeutics (NasdaqGS:SRPT) saw its share price rise by 19% over the past month, a move that notably outpaced the broader market's 1% increase for the week and the 13% gain over the year.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The latest analyst rating for Sarepta Therapeutics (NASDAQ:SRPT) was provided by Scotiabank, and Sarepta Therapeutics upgraded their sector outperform rating. The last upgrade for Sarepta ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...